Please login to the form below

Not currently logged in
Email:
Password:

Boyds appoints Dr Nick Meyers and Natasha Nesterova-Smith

Pharma and biotech consultancy company expands its senior team

Boyds has expanded its senior team, appointing Dr Nick Meyers as programme director and Nastasha Nesterova-Smith as an associate director in regulatory affairs.

Dr Meyers joined Boyds in January, having most recently held senior management positions with Daiichi Sankyo Development, CRO and PPD.

Having worked in the industry for over 20 years, Dr Meyers also brings experience from Phytopharm, where he worked on the treatment of Parkinson's disease and ALS, and Alizyme Therapeutics, where he was responsible for the development of treatment of IBS-C and IBS-A.

Meanwhile, Nesterova-Smith joined Boyds in December 2015 bringing experience as a regulatory professional at Amgen, Genzyme, Parexel, Transkaryotic Therapies and Wyeth.

She has over 14 years' regulatory experience in drug development and registrations for biological and small molecules, clinical development, MMA and lifecycle management for EU centrally approved products.

Alan Boyd, founder and chief executive officer of Boyd's, said: “We are experiencing a period of growth and seeing an increase in work over the past twelve months, particularly in the biological space. I am delighted to welcome Nick and Natasha to the team in support of this growth.”

15th January 2016

From: Regulatory

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
An agency called Owen

We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....

Latest intelligence

New from the PhRMA: Diversity in clinical trials principles summarised
In November 2020, PhRMA announced the first-ever, industry-wide principles on clinical trial diversity. The principles were approved by the PhRMA Boards of Directors and will take effect in April 2021....
New from the FDA: Diversity in clinical trials guidance summarised
In November 2020, the FDA released guidance to enable greater diversity in clinical trials through changes to eligibility criteria, enrolment practices, and trial designs....
5 steps to effective clinical trial branding
When recruiting patients for your clinical trial, you want the materials and information around it to be seen as reputable and professional. To make it clear what the clinical trial...

Infographics